In light of recent concerns surrounding potential rare side effects of the AstraZeneca-Oxford COVID-19 vaccine, the pharmaceutical giant has reiterated its commitment to patient safety while......
United Kingdom-based pharmaceutical major AstraZeneca has started global withdrawal of its COVID-19 vaccine, which was provided in India as 'Covishield' in partnership with Serum Institute of......
United Kingdom-headquartered pharmaceutical giant AstraZeneca (AZ) has admitted that in 'very rare cases' its Covid vaccine can cause a blood clot related side effect but the causal link is......
'It is admitted that the AZ vaccine can, in very rare cases, cause TTS.' IMAGE: A vial labelled 'AstraZeneca COVID-19 Vaccine'. Photograph: Illustration/Dado Ruvic/Reuters The controversial......
The Oxford-AstraZeneca COVID-19 vaccine, known as Vaxzevria in Europe and licensed as Covishield in India, is facing a legal challenge in the high court in London, a UK media report said on......
The institute expects to complete both, phase-2 and 3 trials in India by the end of this year. Pune's Serum Institute of India (SII) is all set to start phase-2 clinical trials of the Oxford......
Amid reports of the ongoing coal shortage in the country, Finance Minister Nirmala Sitharaman stressed that there is no shortage and termed these as “absolutely baseless”, saying India......
The Centre is looking to procure around 1 billion syringes between September and December to support the COVID-19 vaccination drive, reports Sohini Das/Business Standard. IMAGE: A beneficiary......